Syntara develops clinical-stage medicines targeting blood cancers, fibrosis, and inflammation using amine oxidase chemistry.
Syntara has raised $2.7M in total funding. The most recent round was Seed. The last funding was announced in November 2025.
Syntara's investors include Cinder Grove Capital.
Syntara is headquartered in Chicago, United States.
Syntara develops clinical-stage medicines targeting blood cancers, fibrosis, and inflammation using amine oxidase chemistry.
Syntara is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syntara — Funding & Investors." VCBacked, November 3, 2025, https://www.vcbacked.co/company/syntara. Accessed October 5, 2026.
VCBacked. (2025). Syntara — Funding & Investors. Retrieved October 5, 2026, from https://www.vcbacked.co/company/syntara
{{cite web |title=Syntara — Funding & Investors |url=https://www.vcbacked.co/company/syntara |website=VCBacked |access-date=October 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated